Dear colleagues and friends,
Here is Sharing-Obgyn news, N° 965
Kind regards
Serge Rozenberg
Noninferiority of One HPV Vaccine Dose to Two Doses
Aimée R. Kreimer, et al (NEJM December 3, 2025
DOI: 10.1056/NEJMoa2506765
Tested whether a single dose of HPV vaccine would provide similar protection to two doses. Girls 12 – 16 years of age were randomly assigned (1:1:1:1 ratio), to receive one or two doses of a bivalent HPV vaccine or one or two doses of a nonavalent HPV vaccine.
The primary end point was new HPV type 16 or 18 infection occurring from month 12 to month 60 and persisting for at least 6 months.
A total of 20,330 participants were enrolled and underwent randomization, and 3005 unvaccinated participants were enrolled in the survey. The noninferiority analysis showed that one vaccine dose was noninferior to two doses in preventing HPV16 or HPV18 infection. The rate difference between one and two doses of the bivalent vaccine was −0.13 infections per 100 participants (95% confidence interval [CI], −0.45 to 0.15; P<0.001 for noninferiority), and the difference between one and two doses of the nonavalent vaccine was 0.21 infections per 100 participants (95% CI, −0.09 to 0.51; P<0.001 for noninferiority). The vaccine effectiveness was at least 97% in each of the four trial groups. No safety concerns were identified.
Conclusions
One dose of either a bivalent or nonavalent HPV vaccine provided protection against HPV16 or HPV18 infection and was not inferior to two doses. (Funded by the National Cancer Institute and others; ESCUDDO ClinicalTrials.gov number, NCT03180034.)
SHARING-OBGYN is a service that I intend to share with you. The idea is to send short email messages concerning an article that appeared recently and might be of interest to you. The selection of the articles is arbitrary, but there are no commercial interests involved and no conflict of interest.
If you want to be removed from the list of persons to whom these emails are sent please let me know.
If you want to bring comments or add email addresses of friends or colleagues, please feel free to do so.